FINWIRES · TerminalLIVE
FINWIRES

GuoSen Securities Starts Suzhou Zelgen Biopharmaceuticals at Outperform with 121.07 Yuan Price Target

By

Suzhou Zelgen Biopharmaceuticals (SHA:688266) has an average rating of buy and mean price target of 154.25 yuan, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Research

Truist Securities Downgrades Sila Realty Trust to Hold From Buy, Raises Price Target to $30 From $28

Truist Securities Downgrades Sila Realty Trust to Hold From Buy, Raises Price Target to $30 From $28

$SILA
Research

Leerink Downgrades Bio-Techne to Market Perform From Outperform, Price Target is $73

Bio-Techne (TECH) has an average rating of overweight and mean price target of $65.33, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $70.50, Change: $+11.62, Percent Change: +19.74%

$TECH
Research

Evercore ISI Upgrades Bio-Techne to Outperform From In Line, Adjusts Price Target to $73 From $50

Bio-Techne (TECH) has an average rating of overweight and mean price target of $65.33, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TECH